Breaking News

Colby Licenses MannKind’s Delivery Technologies

To develop cancer immunotherapies via intra-lymph node injection

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Colby Pharmaceutical and MannKind have entered a license agreement granting Colby exclusive worldwide rights to develop and commercialize disease-specific antigen compounds and intra-lymph node delivery technologies from MannKind’s MKC1106 active immunotherapy programs. These programs are currently being developed for the treatment of melanoma, prostate, hematological disorders and other cancers.   MannKind will receive an upfront payment and milestones related to the development, approval and c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters